




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 259/10, C07D 295/08, 309/12, A61K 31/165		A1	(11) International Publication Number: WO 99/01426 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13106 (22) International Filing Date: 24 June 1998 (24.06.98) (30) Priority Data: 60/051,440 1 July 1997 (01.07.97)		US	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BARRETT, Stephen, Douglas [US/US]; 14220 Sunbury, Livonia, MI 48154 (US). BRIDGES, Alexander, James [GB/US]; 3301 Textile Road, Saline, MI 48176 (US). DOHERTY, Annette, Marian [US/FR]; 33, rue Poussin, F-75016 Paris (FR). DUDLEY, David, Thomas [US/US]; 3201 Hays Court, Ann Arbor, MI 48108 (US). SALTIEL, Alan, Robert [US/US]; 2002 Valley View Drive, Ann Arbor, MI 48105 (US). TECLE, Haile [US/US]; 3048 Turnberry, Ann Arbor, MI 48108 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			

(54) Title: 4-BROMO OR 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors



(57) Abstract

Phenylamino benzhydroxamic acid derivatives of formula (I) where R₁, R₂, R₃, R₄, R₅, and R₆ are hydrogen or substituent groups such as alkyl, and where R₇ is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	R	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS

FIELD OF THE INVENTION

This invention provides certain hydroxamic acid derivatives of anthranilic acids which inhibit certain dual specificity kinase enzymes involved in 5 proliferative diseases such as cancer and restenosis.

BACKGROUND OF THE INVENTION

Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins. Cancer, for 10 example, is commonly caused by a series of defects in these signaling proteins, resulting from a change either in their intrinsic activity or in their cellular concentrations. The cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can 15 lead to spurious mitogenic signals within the cell. Some of the most common mutations occur in genes encoding the protein known as Ras, which is a G-protein that is activated when bound to GTP, and inactivated when bound to GDP.

The above mentioned growth factor receptors, and many other mitogenic receptors, when activated, lead to Ras being converted from the GDP-bound state 20 to the GTP-bound state. This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras.GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated.

Activated Ras leads in turn to the activation of a cascade of serine/ 25 threonine kinases. One of the groups of kinases known to require an active Ras.GTP for its own activation is the Raf family. These in turn activate MEK, which then activates MAP kinase. Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is

-2-

sufficient to induce cellular transformation. Blockade of downstream Ras signaling, for example by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants. Although Ras is not itself a protein kinase, it 5 participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism. Once activated, Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, S²¹⁸ and S²²² in the case of MEK-1, which are the prerequisite for activation of MEK as a kinase. MEK in turn phosphorylates MAP kinase on both a tyrosine, Y¹⁸⁵, and a threonine 10 residue, T¹⁸³, separated by a single amino acid. This double phosphorylation activates MAP kinase at least 100-fold, and it can now catalyze the phosphorylation of a large number of proteins, including several transcription factors and other kinases. Many of these MAP kinase phosphorylations are mitogenically activating for the target protein, whether it be another kinase, a 15 transcription factor, or other cellular protein. MEK is also activated by several kinases other than Raf-1, including MEKK, and itself appears to be a signal integrating kinase. As far as is currently known, MEK is highly specific for the phosphorylation of MAP kinase. In fact, no substrate for MEK other than MAP kinase has been demonstrated to date, and MEK does not phosphorylate peptides 20 based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase. MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this requirement and the unusual specificity of MEK are suggestive that it may have 25 enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade of the ATP binding site, may be found.

This invention provides compounds which are highly specific inhibitors of the kinase activity of MEK. Both in enzyme assays and whole cells, the 30 compounds inhibit the phosphorylation of MAP kinase by MEK, thus preventing the activation of MAP kinase in cells in which the Ras cascade has been activated. The results of this enzyme inhibition include a reversal of transformed phenotype

-3-

of some cell types, as measured both by the ability of the transformed cells to grow in an anchorage-independent manner and by the ability of some transformed cell lines to proliferate independently of external mitogens.


5 The compounds provided by this invention are phenylamino benzhydroxamic acid derivatives in which the phenyl ring is substituted at the 4-position with bromo or iodo. United States Patent No. 5,155,110 discloses a wide variety of fenamic acid derivatives, including certain phenylamino benzhydroxamic acid derivatives, as anti-inflammatory agents. The reference fails to describe the compound of this invention or their kinase inhibitory activity.

10

SUMMARY OF THE INVENTION

This invention provides 4-bromo and 4-iodo phenylamino benzhydroxamic acid derivatives which are kinase inhibitors and as such are useful for treating proliferative diseases such as cancer, psoriasis, and restenosis. The compounds are defined by Formula I

15



wherein:

R₁ is hydrogen, hydroxy, C₁-C₈ alkyl, C₁-C₈ alkoxy, halo, trifluoromethyl, or

CN;

R₂ is hydrogen;

20 R₃, R₄, and R₅ independently are hydrogen, hydroxy, halo, trifluoromethyl,

C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, CN, or (O or NH)_m-(CH₂)_n-R₉, where

R₉ is hydrogen, hydroxy, CO₂H or NR₁₀R₁₁;

n is 0 to 4;

-4-

m is 0 or 1;

R₁₀ and R₁₁ independently are hydrogen or C₁-C₈ alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N-C₁-C₈ alkyl;

5

R₆ is hydrogen, C₁-C₈ alkyl, C-C₁-C₈ alkyl, aryl, aralkyl, or C₃-C₁₀ cycloalkyl;

10

R₇ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₁₀ (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or NR₉); or R₆ and R₇ taken together with the N-O to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or


15

NR₁₀R₁₁;

and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by cycloalkyl (or cycloalkyl optionally containing a heteroatom selected from O, S, or NR₉), aryl, aryloxy, heteroaryl, or heteroaryloxy.

20

Preferred compounds have Formula II




where R₁, R₃, R₄, R₅, R₆, and R₇ are as defined above. Especially preferred are compounds wherein R₁ is methyl or halo, and R₃, R₄, and R₅ are halo such as fluoro or bromo.

25


Another preferred group of compounds have Formula III

-5-



wherein R₁, R₃, R₄, R₅, and R₇ are as defined above.

The most preferred compounds are those wherein R₁ is methyl or halo such as F, Br, Cl, and I, R₃ is hydrogen or halo such as fluoro, R₄ is halo such as 5 fluoro, and R₅ is hydrogen or halo such as fluoro or bromo. Such compounds have the formulas



Specific compounds provided by the invention include the following:

10 3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
 5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
 15 N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

-6-

3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-
benzamide;
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-
benzamide;
2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-
benzamide;
5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-
benzamide;
2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide;
2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-
benzamide;
2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-
benzamide;
5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-
phenylamino)-benzamide;
5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-
phenylamino)-benzamide;
N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-
benzamide;
N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-
benzamide;

5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

5 N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluoro-benzamide

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide;

20 N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

25 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

30 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-isopropyl-benzamide;

-8-

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide;

5 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide

10 (HCl salt);

2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide;

15 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

20 3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

25 5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; and

5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide.

30 This invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable excipient, diluent, or carrier. Preferred formulations include any of the foregoing preferred compounds together with an excipient, diluent, or carrier.

The compounds of Formula I are potent and selective inhibitors of kinase enzymes, particularly MEK₁ and MEK₂. They are, therefore, useful to treat subjects suffering from cancer and other proliferative diseases such as psoriasis, restenosis, autoimmune disease, and atherosclerosis. The compounds are especially well-suited to treat cancers such as breast cancer, colon cancer, prostate cancer, skin cancer, and pancreatic cancer. The compounds can also be used to treat stroke, diabetes, hepatomegaly, cardiomegaly, Alzheimer's disease, cystic fibrosis, and viral disease. The invention provides a method of inhibiting MEK enzymes and the foregoing diseases by administering to a subject an effective amount of a compound of Formula I.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "aryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from five to twelve carbon atoms. Examples of typical aryl groups include phenyl, naphthyl, and fluorenyl. The aryl may be substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, or amino. Typical substituted aryl groups include 3-fluorophenyl, 3,5-dimethoxyphenyl, 4-nitronaphthyl, 2-methyl-4-chloro-7-aminofluorenyl, and the like.

The term "aryloxy" means an aryl group bonded through an oxygen atom, for example phenoxy, 3-bromophenoxy, naphthoxy, and 4-methyl-1-fluorenyloxy.

"Heteroaryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from four to eleven carbon atoms and one, two, or three heteroatoms selected from O, S, or N. Examples include furyl, thienyl, pyrrolyl, pyrazolyl, triazolyl, thiazolyl, xanthenyl, pyronyl, indolyl, pyrimidyl, naphthyridyl, pyridyl, and triazinyl. The heteroaryl groups can be unsubstituted or substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, or amino. Examples of substituted heteroaryl groups include chloropyranyl, methylthienyl, fluoropyridyl, amino-1,4-benzisoxazinyl, nitroisoquinolinyl, and hydroxyindolyl.

-10-

The heteroaryl groups can be bonded through oxygen to make heteroaryloxy groups, for example thienyloxy, isothiazolyloxy, benzofuranyloxy, pyridyloxy, and 4-methylisoquinolinylloxy.

The term "C₁-C₈ alkyl" means straight and branched chain aliphatic groups having from one to eight carbon atoms. Typical C₁-C₈ alkyl groups 5 include methyl, ethyl, isopropyl, tert.-butyl, 2,3-dimethylhexyl, and 1,1-dimethylpentyl. The alkyl groups can be unsubstituted or substituted by cycloalkyl, cycloalkyl containing a heteroatom selected from O, S, or NR₉, aryl, aryloxy, heteroaryl, or heteroaryloxy, as those terms are defined above. Examples 10 of aryl and aryloxy substituted alkyl groups include phenylmethyl, 2-phenylethyl, 3-chlorophenylmethyl, 1,1-dimethyl-3-(2-nitrophenoxy)butyl, and 3,4,5-trifluoronaphthylmethyl. Examples of alkyl groups substituted by a heteroaryl or heteroaryloxy group include thienylmethyl, 2-furylethyl, 6-furyloxyoctyl, 4-methylquinoloxymethyl, and 6-isothiazolylhexyl. Cycloalkyl 15 substituted alkyl groups include cyclopropylmethyl, 2-cyclopentylethyl, 2-piperidin-1-ylethyl, 3-(tetrahydropyran-2-yl)propyl, and cyclobutylmethyl.

"C₂-C₈ Alkenyl" means a straight or branched carbon chain having one or 20 more double bonds. Examples include but-2-enyl, 2-methyl-prop-2-enyl, 1,1-dimethyl-hex-4-enyl, 3-ethyl-4-methyl-pent-2-enyl, and 3-isopropyl-pent-4-enyl. The alkenyl groups can be substituted with aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 3-phenylprop-2-enyl, 6-thienyl-hex-2-enyl, 2-furyloxy-but-2-enyl, and 4-naphthoxy-hex-2-enyl.

"C₂-C₈ Alkynyl" means a straight or branched carbon chain having from 25 two to eight carbon atoms and at least one triple bond. Typical alkynyl groups include prop-2-ynyl, 2-methyl-hex-5-ynyl, 3,4-dimethyl-hex-5-ynyl, and 2-ethyl-but-3-ynyl. The alkynyl groups can be substituted by aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 4-(2-fluorophenyl)-but-3-ynyl, 3-methyl-5-thienylpent-4-ynyl, 3-phenoxy-hex-4-ynyl, and 2-furyloxy-3-methyl-hex-4-ynyl.

30 The alkenyl and alkynyl groups can have one or more double bonds or triple bonds, respectively, or a combination of double and triple bonds. For

-11-

example, typical groups having both double and triple bonds include hex-2-en-4-ynyl, 3-methyl-5-phenylpent-2-en-4-ynyl, and 3-thienyloxy-hex-3-en-5-ynyl.


The term "C₃-C₁₀ cycloalkyl" means a non-aromatic ring or fused rings containing from three to ten carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, bicycloheptyl, adamantlyl, and cyclohexyl. The ring can optionally contain a heteroatom selected from O, S, or NR₉. Such groups include tetrahydrofuryl, tetrahydropyrrolyl, octahydrobenzofuranyl, octahydroindolyl, and octahydrobenzothiophuranyl.

R₃, R₄, and R₅ can include groups defined by the term (O or NH)_m-(CH₂)_n-R₉. Examples of such groups are aminomethyl, 2-aminoethyl, 2-aminoethylamino, 3-aminopropoxy, N,N-diethylamino, 3-(N-methyl-N-isopropylamino)-propylamino, 2-(N-acetylamino)-ethoxy, 4-(N-dimethylaminocarbonylamino)-butoxy, and 3-(N-cyclopropylamino)-propoxy.

The 4-bromo and 4-iodo phenylamino benzhydroxamic acid derivatives of Formula I can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry. A typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a phenylamino benzoic acid, and then reacting the benzoic acid phenylamino derivative with a hydroxylamine derivative. This process is depicted in Scheme 1.

-12-

Scheme 1



where L is a leaving group, for example halo such as fluoro, chloro, bromo or 5
iodo, or an activated hydroxy group such as a diethylphosphate, trimethylsilyloxy, p-nitrophenoxy, or phenylsulfonyloxy.

The reaction of the aniline derivative and the benzoic acid derivative generally is accomplished by mixing the benzoic acid with an equimolar quantity 10 or excess of the aniline in an unreactive organic solvent such as tetrahydrofuran, or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, and sodium amide. The reaction generally is carried out at a temperature of about -78°C to about 25°C, and normally is complete within

-13-


about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.

5 The phenylamino benzoic acid next is reacted with a hydroxylamine derivative HNR_6OR_7 in the presence of a peptide coupling reagent. Hydroxylamine derivatives that can be employed include methoxylamine, N-ethyl-isopropoxy amine, and tetrahydro-oxazine. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ),
10 1,3-dicyclohexylcarbodiimide (DCC), bromo-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP) and (benzotriazolyloxy)tritypyrrolidino phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and hydroxylamino derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, 15 tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the coupling reagent is added. A base such as triethylamine or diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, 20 and purifying the product by standard methods such as chromatography or crystallizations from solvents such as acetone, diethyl ether, or ethanol.

25 An alternative method for making the invention compounds involves first converting a benzoic acid to a hydroxamic acid derivative, and then reacting the hydroxamic acid derivative with an aniline. This synthetic sequence is depicted in Scheme 2.

-14-

Scheme 2




where L is a leaving group. The general reaction conditions for both of the steps in Scheme 2 are the same as those described above for Scheme 1.

5 Yet another method for making invention compounds comprises reacting a phenylamino benzylhydroxamic acid with an ester forming group as depicted in Scheme 3.

-15-

Scheme 3



where L is a leaving group such as halo, and a base is triethylamine or diisopropylamine.

5 The synthesis of invention compounds of Formula I is further illustrated by the following detailed examples.

EXAMPLE 1

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

10 (a) Preparation of 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid

To a stirred solution containing 3.16 g (0.0133 mol) of 2-amino-

5-iodotoluene in 5 mL of tetrahydrofuran at -78°C was added 10 mL (0.020 mol)

of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene

(Aldrich) solution. The resulting green suspension was stirred vigorously for

15 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of

2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction

-16-

2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature the mixture was stirred for 2 days. The reaction mixture was concentrated by evaporation of the solvent under reduced pressure. Aqueous HCl

5 (10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried (MgSO_4) and then concentrated over a steambath to low volume (10 mL) and cooled to room temperature. The off-white fibers which formed were collected by vacuum filtration, rinsed with hexane, and dried in a vacuum-oven (76°C; ca. 10 mm of Hg) to afford 1.10 g

10 (47%) of the desired material; mp 224-229.5°C;

^1H NMR (400 MHz, DMSO): δ 9.72 (s, 1H), 7.97 (dd, 1H, $J=7.0, 8.7$ Hz), 7.70 (d, 1H, $J=1.5$ Hz), 7.57 (dd, 1H, $J=8.4, 1.9$ Hz), 7.17 (d, 1H, $J=8.2$ Hz), 6.61-6.53 (m, 2H), 2.18 (s, 3H);

^{13}C NMR (100 MHz, DMSO): δ 169.87, 166.36 (d, $J_{\text{C}-\text{F}}=249.4$ Hz), 150.11 (d, $J_{\text{C}-\text{F}}=11.4$ Hz), 139.83, 138.49, 136.07, 135.26 (d, $J_{\text{C}-\text{F}}=11.5$ Hz), 135.07, 125.60, 109.32, 104.98 (d, $J_{\text{C}-\text{F}}=21.1$ Hz), 99.54 (d, $J_{\text{C}-\text{F}}=26.0$ Hz), 89.43, 17.52;

^{19}F NMR (376 MHz, DMSO): δ -104.00 to -104.07 (m);

IR (KBr) 1670 (C=O stretch) cm^{-1} ;

MS (CI) $\text{M}+1 = 372$.

20 Analysis calculated for $\text{C}_{14}\text{H}_{11}\text{FINO}_2$:

C, 45.31; H, 2.99; N, 3.77.

Found: C, 45.21; H, 2.77; N, 3.64.

(b) **Preparation of 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**

25 To a stirred solution of 4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.6495 g, 0.001750 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.2590 g, 0.002211 mol), and diisopropylethylamine (0.40 mL, 0.0023 mol) in 31 mL of an equivolume tetrahydrofuran-dichloromethane solution was added 1.18 g (0.00227 mol) of solid PyBOP ([benzotriazolyloxy]tritypyrrolidino

30 phosphonium hexafluorophosphate, Advanced ChemTech) directly. The reaction mixture was stirred for 30 minutes after which time it was concentrated in vacuo.

-17-

The brown oil was treated with 10% aqueous hydrochloric acid. The suspension was extracted with ether. The organic extraction was washed with 10% sodium hydroxide followed by another 10% hydrochloric acid wash, was dried (MgSO_4) and concentrated in vacuo to afford 1.0 g of a light-brown foam. This intermediate
5 was dissolved in 25 mL of ethanolic hydrogen chloride, and the solution was allowed to stand at room temperature for 15 minutes. The reaction mixture was concentrated in vacuo to a brown oil that was purified by flash silica chromatography. Elution with dichloromethane \rightarrow dichloromethane-methanol (166:1) afforded 0.2284 g of a light-brown viscous oil. Scratching with pentane-hexanes and drying under high vacuum afforded 0.1541 g (23%) of an off-white
10 foam; mp 61-75°C;

15 ^1H NMR (400 MHz, DMSO): δ 11.34 (s, 1H), 9.68 (s, 1H), 9.18 (s, 1H), 7.65 (d, 1H, J =1.5 Hz), 7.58 (dd, 1H, J =8.7, 6.8 Hz), 7.52 (dd, 1H, J =8.4, 1.9 Hz), 7.15 (d, 1H, J =8.4 Hz), 6.74 (dd, 1H, J =11.8, 2.4 Hz), 6.62 (ddd, 1H, J =8.4, 8.4, 2.7 Hz), 2.18 (s, 3H);

16 ^{13}C NMR (100 MHz, DMSO): δ 165.91, 164.36 (d, $J_{\text{C}-\text{F}}=247.1$ Hz), 146.78, 139.18, 138.77, 135.43, 132.64, 130.60 (d, $J_{\text{C}-\text{F}}=11.5$ Hz), 122.23, 112.52, 104.72 (d, J =22.1 Hz), 100.45 (d, $J_{\text{C}-\text{F}}=25.2$ Hz), 86.77, 17.03;

17 ^{19}F NMR (376 MHz, DMSO): δ -107.20 to -107.27 (m);
IR (KBr) 3307 (broad, O-H stretch), 1636 (C=O stretch) cm^{-1} ;
MS (CI) $\text{M}+1 = 387$.

Analysis calculated for $\text{C}_{14}\text{H}_{12}\text{FIN}_2\text{O}_2$:

C, 43.54; H, 3.13; N, 7.25.

Found: C, 43.62; H, 3.24; N, 6.98.

25

EXAMPLE 2

5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide

(a) Preparation of 5-Br mo-2,3,4-trifluorobenzoic acid

To a stirred solution comprised of 1-bromo-2,3,4-trifluorobenzene
30 (Aldrich, 99%; 5.30 g, 0.0249 mol) in 95 mL of anhydrous tetrahydrofuran cooled

-18-

to -78°C was slowly added 12.5 mL of 2.0 M lithium diisopropylamide in heptane/tetrahydrofuran/ethylbenzene solution (Aldrich). The mixture was stirred for 1 hour and transferred by canula into 700 mL of a stirred saturated ethereal carbon dioxide solution cooled to -78°C. The cold bath was removed, and the reaction mixture was stirred for 18 hours at ambient temperature. Dilute (10%) aqueous hydrochloric acid (ca. 500 mL) was poured into the reaction mixture, and the mixture was subsequently concentrated on a rotary evaporator to a crude solid. The solid product was partitioned between diethyl ether (150 mL) and aq. HCl (330 mL, pH 0). The aqueous phase was extracted with a second portion (100 mL) of diethyl ether, and the combined ethereal extracts were washed with 5% aqueous sodium hydroxide (200 mL) and water (100 mL, pH 12). These combined alkaline aqueous extractions were acidified to pH 0 with concentrated aqueous hydrochloric acid. The resulting suspension was extracted with ether (2 × 200 mL). The combined organic extracts were dried ($MgSO_4$), concentrated in vacuo, and subjected to high vacuum until constant mass was achieved to afford 5.60 g (88% yield) of an off-white powder; mp 139-142.5°C; 1H NMR (400 MHz, DMSO): δ 13.97 (broad s, 1H, 8.00-7.96 (m, 1H); ^{13}C NMR (100 MHz, DMSO): δ 162.96, 129.34, 118.47, 104.54 (d, $J_{C-F}=22.9$ Hz); ^{19}F NMR (376 MHz, DMSO): δ -120.20 to -120.31 (m), -131.75 to -131.86 (m), -154.95 to -155.07 (m); IR (KBr) 1696 (C=O stretch) cm^{-1} ; MS (CI) $M+1 = 255$. Analysis calculated for $C_{74}H_{21}BrF_3O_2$:

25 C, 32.97; H, 0.79; N, 0.00; Br, 31.34; F, 22.35.
Found: C, 33.18; H, 0.64; N, 0.01; Br, 30.14; F, 22.75.

(b) **Preparation of 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid**

To a stirred solution comprised of 1.88 g (0.00791 mol) of 2-amino-5-iodotoluene in 10 mL of tetrahydrofuran at -78°C was added 6 mL (0.012 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene

-19-

(Aldrich) solution. The resulting green suspension was stirred vigorously for 10 minutes, after which time a solution of 1.00 g (0.00392 mol) of 5-bromo-2,3,4-trifluorobenzoic acid in 15 mL of tetrahydrofuran was added. The cold bath was subsequently removed, and the reaction mixture stirred for 18 hours. The 5 mixture was concentrated, and the concentrate was treated with 100 mL of dilute (10%) aqueous hydrochloric acid. The resulting suspension was extracted with ether (2 × 150 mL), and the combined organic extractions were dried (MgSO_4) and concentrated in vacuo to give an orange solid. The solid was triturated with boiling dichloromethane, cooled to ambient temperature, and collected by 10 filtration. The solid was rinsed with dichloromethane, and dried in the vacuum-oven (80°C) to afford 1.39 g (76%) of a yellow-green powder; mp 259.5-262°C; ^1H NMR (400 MHz, DMSO): δ 9.03 (s, 1H), 7.99 (dd, 1H, $J=7.5, 1.9$ Hz), 7.57 (dd, 1H, $J=1.5$ Hz), 7.42 (dd, 1H, $J=8.4, 1.9$ Hz), 6.70 (dd, 1H, $J=8.4, 6.0$ Hz), 2.24 (s, 3H); 15 ^{19}F NMR (376 MHz, DMSO): δ -123.40 to -123.47 (m); -139.00 to -139.14 (m); IR (KBr) 1667 (C=O stretch) cm^{-1} ; MS (CI) $\text{M}+1 = 469$. Analysis calculated for $\text{C}_{14}\text{H}_9\text{BrF}_2\text{INO}_2$: C, 35.93; H, 1.94; N, 2.99; Br, 17.07; F, 8.12; I, 27.11. Found: C, 36.15; H, 1.91; N, 2.70; Br, 16.40; F, 8.46; I, 26.05.

(c) **Preparation of 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**

To a stirred solution comprised of 5-bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-benzoic acid (0.51 g, 0.0011 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.15 g, 0.0013 mol), and diisopropylethylamine (0.25 mL, 0.0014 mol) in 20 mL of an equimolar tetrahydrofuran-dichloromethane solution was added 0.6794 g (0.001306 mol) of solid PyBOP (Advanced ChemTech) directly. The reaction mixture was stirred at 24°C for 10 minutes, and then was concentrated to dryness in vacuo. The concentrate was 25 suspended in 100 mL of 10% aqueous hydrochloric acid. The suspension was 30 extracted with 125 mL of diethyl ether. The ether layer was separated, washed

-20-

with 75 mL of 10% aqueous sodium hydroxide, and then with 100 mL of dilute acid. The ether solution was dried (MgSO_4) and concentrated in vacuo to afford 0.62 g (100%) of an off-white foam. The foam was dissolved in ca. 15 mL of methanolic hydrogen chloride. After 5 minutes, the solution was concentrated in vacuo to an oil, and the oil was purified by flash silica chromatography. Elution with dichloromethane \rightarrow dichloromethane-methanol (99:1) afforded 0.2233 g (42%) of a yellow powder. The powder was dissolved in diethyl ether and washed with dilute hydrochloric acid. The organic phase was dried (MgSO_4) and concentrated in vacuo to afford 0.200 g of a foam. This product was triturated with pentane to afford 0.1525 g of a powder that was repurified by flash silica chromatography. Elution with dichloromethane afforded 0.0783 g (15%) of an analytically pure title compound, mp 80-90°C;

10 ^1H NMR (400 MHz, DMSO): δ 11.53 (s, 1H), 9.38 (s, 1H), 8.82 (s, 1H), 7.70 (dd, 1H, J =7.0, 1.9 Hz), 7.53 (s, 1H), 7.37 (dd, 1H, J =8.4, 1.9 Hz), 6.55 (dd, 1H, J =8.2, 15 6.5 Hz), 2.22 (s, 3H);

19F NMR (376 MHz, DMSO): δ -126.24 to -126.29 (m), -137.71 to -137.77 (m);

IR (KBr) 3346 (broad, O-H stretch), 1651 (C=O stretch) cm^{-1} ;

MS (CI) $\text{M}+1 = 484$.

Analysis calculated for $\text{C}_{14}\text{H}_{10}\text{BrF}_2\text{IN}_2\text{O}_2$:

20 C, 34.81; H, 2.09; N, 5.80.

Found: C, 34.53; H, 1.73; N, 5.52,

Examples 3 to 12 and 78 to 102 in the table below were prepared by the general procedures of Examples 1 and 2.

EXAMPLES 13-77

25 Examples 13 to 77 were prepared utilizing combinatorial synthetic methodology by reacting appropriately substituted phenylamino benzoic acids

R_6

(e.g., as shown in Scheme 1) and hydroxylamines (e.g., HN-O-R_7). A general

30 method is given below:

To a 0.8 mL autosampler vial in a metal block was added 40 μL of a 0.5 M solution of the acid in DMF and 40 μL of the hydroxylamine (2 M solution in

-21-

Hunig's base and 1 M in amine in DMF). A 0.5 M solution of PyBrop was freshly prepared, and 50 μ L were added to the autosampler vial. The reaction was allowed to stand for 24 hours.

5 The reaction mixture was transferred to a 2 dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water and the water layer washed again with 2 mL of ethyl acetate. The combined organic layers were allowed to evaporate to dryness in an open fume hood.

10 The residue was taken up in 2 mL of 50% acetonitrile in water and injected on a semi-prep reversed phase column (10 mm \times 25 cm, 5 μ M spherical silica, pore Size 115 A derivatised with C-18, the sample was eluted at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100% acetonitrile continued for 8 minutes.) Fractions were collected by monitoring at 214 nM. The desired fractions were evaporated using a Zymark Turbovap. The product was dissolved in chloroform and transferred to a preweighed vial, 15 evaporated, and weighed again to determine the yield. The structure was confirmed by mass spectroscopy.

EXAMPLES 3-102

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
3	2-(4-bromo-2-methyl-phenylamino)-4-fluoro-N-hydroxy-benzamide	56-75 dec	523
4	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide	65 dec	
5	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	62-67	
6	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	105-108	

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
7	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxybenzamide	64-68	
8	4-Fluoro-N-hydroxy-2-(4-fluoro-2-methyl-phenylamino)-benzamide	119-135	
9	4-Fluoro-N-hydroxy-2-(2-methyl phenylamino)-benzamide	101-103	
10	4-Fluoro-2-(4-fluor-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	142-146	
11	4-Fluoro-N-hydroxy-2-(4-cluoro-2-methyl-phenylamino)-benzamide	133.5-135	
12	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide	107-109.5	
13	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide	399	
14	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide	417	
15	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-methoxy-benzamide	369	
16	2-(4-Bromo-2-methyl-phenylamino)-N-ethoxy-3,4-difluoro-benzamide	342*	(M-EtO)

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
17	5-Bromo-N-ethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		509
18	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		445
19	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-isopropoxy-benzamide		397
20	4-Fluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		465
21	3,4-Difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		483
22	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(furan-3-ylmethoxy)-benzamide		435
23	5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		561
24	5-Bromo-N-(but-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		536
25	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		423
26	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		441

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
27	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)- N-(1-methyl-prop-2-ynyl)-benzamide		455
28	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-(1-methyl-prop-2-ynyl)- benzamide		407
29	N-(But-3-ynyl)-3,4-difluoro-2-(4-iodo- 2-methyl-phenylamino)-benzamide		455
30	2-(4-Bromo-2-methyl-phenylamino)-N-(but- 3-ynyl)-3,4-difluoro-benzamide		407
31	5-Bromo-N-(but-3-ynyl)-3,4-difluoro- 2-(4-iodo-2-methyl-phenylamino)-benzamide		533
32	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)- N-(3-phenyl-prop-2-ynyl)-benzamide		517
33	3,4-Difluoro-2-(4-bromo-2-methyl- phenylamino)-N-(3-phenyl-prop-2-ynyl)- benzamide		469
34	3,4-Difluoro-N-[3-(3-fluoro-phenyl)-prop- 2-ynyl]-2-(4-iodo-2-methyl-phenylamino)- benzamide		535
35	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-[3-(3-fluoro-phenyl)-prop-		487

-25-

2-ynyoxy]-benzamide

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
36	3,4-Difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyoxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		535
37	5-Bromo-3,4-difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyoxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		613
39	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-methyl-5-phenyl-pent-2-en-4-ynyoxy)-benzamide		510
40	N-Ethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		431
41	2-(4-Bromo-2-methyl-phenylamino)-N-ethoxy-3,4-difluoro-benzamide		383
42	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		427
43	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		445
44	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-propoxy-benzamide		397
45	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-propoxy-benzamide		523

-26-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
46	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		427
47	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		445
48	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-isopropoxy-benzamide		397
49	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		523
50	N-Cyclobutyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
51	2-(4-Bromo-2-methyl-phenylamino)-N-cyclobutyloxy-3,4-difluoro-benzamide		409
52	N-Cyclopentyloxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		453
53	N-Cyclopentyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		471
54	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopentyloxy-3,4-difluoro-benzamide		423
55	N-Cyclopropylmethoxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439

-27-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
56	N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
57	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide		409
58	5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)		435
59	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		505
60	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		523
61	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-phenoxy-ethoxy)-benzamide		475
62	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		481
63	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		499
64	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(thiophen-2-ylmethoxy)-benzamide		451
65	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		439

-28-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
66	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		457
67	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-methyl-allyloxy)-benzamide		410
68	N-(But-2-enyloxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439
69	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
70	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410
71	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-nyloxy)-benzamide		441
72	N-(But-3-nyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		455
73	2-(4-Bromo-2-methyl-phenylamino)-N-(4,4-dimethyl-pent-2-nyloxy)-3,4-difluoro-benzamide		449
74	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
75	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410

-29-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
76	N-(3-tert.-butyl-propyn-2-yl)oxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	479	
77	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide	577*	*CI
78	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-isopropyl-benzamide	oil	
79	N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	125-127	
80	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	45-55	
81	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	208-209 (GLASS)	
82	2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide	199-200	
83	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide	163-165	
84	3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide	65-75	
85	3,4-Difluoro-5-bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethoxy)-benzamide	95	

-30-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
86	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide	167-169	
87	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide (HCl salt)	165-169	
88	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide	166-167.5	
89	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide	173-174	
90	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide	121-122	
91	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt	206-211.5 DEC	
92	5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	95-105	
93	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide	266-280 DEC	

-31-

Example No.	Compound	Melting Point (°C)	MS (M-H ⁺)
94	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide	167.5-169.5	
95	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide	172.5-173.5	
96	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide	171-172.5	
97	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethoxy)-benzamide	173.5-175	
98	5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl-phenylamino)-benzamide	81 DEC	
99	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isobutoxy-benzamide	126-128	
100	5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	139-142	
101	5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	113-115	
102	5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	138-139	

-32-

The invention compounds are useful in treating cancer and other proliferative diseases by virtue of their selective inhibition of the dual specificity protein kinases MEK₁ and MEK₂. The invention compound has been evaluated in a number of biological assays which are normally utilized to establish inhibition of proteins and kinases, and to measure mitogenic and metabolic responses to such inhibition.

Enzyme Assays

Cascade assay for inhibitors of the MAP kinase pathway

Incorporation of ^{32}P into myelin basic protein (MBP) was assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase fusion protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl₂, 1 mM MnCl₂, 1 mM EGTA, 50 μM [γ - ^{32}P]ATP, 10 μg GST-MEK, 0.5 μg GST-MAPK and 40 μg MBP in a final volume of 100 μL . Reactions were stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. ^{32}P retained on the filter mat was determined using a 1205 Betaplate. Compounds were assessed at 10 μM for ability to inhibit incorporation of ^{32}P .

To ascertain whether compounds were inhibiting GST-MEK or GST MAPK, two additional protocols were employed. In the first protocol, compounds were added to tubes containing GST-MEK, followed by addition of GST-MAPK, MBP and [γ - ^{32}P]ATP. In the second protocol, compounds were added to tubes containing both GST-MEK and GST-MAPK, followed by MBP and [γ - ^{32}P]ATP. Compounds that showed activity in both protocols were scored as MAPK inhibitors, while compounds showing activity in only the first protocol were scored as MEK inhibitors.

In vitro MAP kinase assay

Inhibitory activity was also confirmed in direct assays. For MAP kinase, 1 μg GST-MAPK was incubated with 40 μg MBP for 15 minutes at 30°C in a

-33-

final volume of 50 μ L containing 50 mM Tris (pH 7.5), 10 μ M MgCl₂, 2 μ M EGTA, and 10 μ M [γ -³²P]ATP. The reaction was stopped by addition of Laemmli SDS sample buffer and phosphorylated MBP resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into MBP was determined by autoradiography, and subsequently by excision of the bands followed by scintillation counting.

In vitro MEK assay

For evaluation of direct MEK activity, 10 μ g GST-MEK1 was incubated with 5 μ g of a glutathione S-transferase fusion protein containing p44MAP kinase with a lysine to alanine mutation at position 71 (GST-MAPK-KA). This mutation eliminates kinase activity of MAPK, so only kinase activity attributed to the added MEK remains. Incubations were 15 minutes at 30°C in a final volume of 50 μ L containing 50 mM Tris (pH 7.5), 10 μ M MgCl₂, 2 μ M EGTA, and 10 μ M [γ -³²P]ATP. The reaction was stopped by addition of Laemmli SDS sample buffer and phosphorylated GST-MAPK-KA was resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into GST-MAPK-KA was determined by autoradiography, and subsequently by excision of the bands followed by scintillation counting. Additionally, an artificially activated MEK was utilized that contained serine to glutamate mutations at positions 218 and 222 (GST-MEK-2E). When these sites are phosphorylated, MEK activity is increased. Phosphorylation of these sites can be mimicked by mutation of the serine residues to glutamate. For this assay, 5 μ g GST-MEK-2E was incubated with 5 μ g GST-MAPK-KA for 15 minutes at 30°C in the same reaction buffer as described above. Reactions were terminated and analyzed as above.

25 Whole cell MAP kinase assay

To determine if compounds were able to block activation of MAP kinase in whole cells, the following protocol was used: Cells were plated in multi-well plates and grown to confluence. Cells were then serum-deprived overnight. Cells were exposed to the desired concentrations of compound or vehicle (DMSO) for 30 minutes, followed by addition of a growth factor, eg, PDGF (100 ng/mL).

-34-

After a 5-minute treatment with the growth factor, cells were washed with PBS, then lysed in a buffer consisting of 70 mM NaCl, 10 mM HEPES (pH 7.4), 50 mM glycerol phosphate, and 1% Triton X-100. Lysates were clarified by centrifugation at 13,000 \times g for 10 minutes. Five micrograms of the resulting supernatants were incubated with 10 μ g microtubule associated protein-2 (Map2) for 15 minutes at 30°C in a final volume of 25 μ L containing 50 mM Tris (pH 7.4), 10 mM MgCl₂, 2 mM EGTA and 30 μ M [γ -³²P]ATP. Reactions were 5 terminated by addition of Laemmli sample buffer. Phosphorylated Map2 was resolved on 7.5% acrylamide gels and incorporated radioactivity determined by 10 autoradiography and subsequent excision of the bands followed by scintillation counting.

Immunoprecipitation and antiphosphotyrosine immunoblots

To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific 15 antibody, and the resulting immunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000 \times g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 μ L of 1% SDS containing 1 mM NaVO₄. 20 Following alternate boiling and vortexing to denature cellular protein, 900 μ L RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate, and 10 mM EDTA) was added. To this mixture was added 60 μ L agarose beads coupled with rabbit immunoglobulin G and 60 μ L Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was 25 incubated at 4°C for 15 minutes then centrifuged at 13,000 \times g for 10 minutes. The resulting supernatant was transferred to fresh tubes and incubated with 10 μ L of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4°C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4°C. The beads were pelleted by centrifugation at 13,000 \times g for 5 minutes and washed three times with 1 mL RIPA buffer. Laemmli sample buffer

-35-

was added to the final bead pellet. This mixture was boiled for 5 minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1% ovalbumin and 1% bovine serum albumin in TBST (150 mM NaCl, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available antibody directed against phosphotyrosine. Antibody bound on the membrane was detected by incubation with ^{125}I -protein A, followed by autoradiography.

Cell Growth Assays

10 ^{3}H -Thymidine incorporation

Cells were plated in multi-well plates and grown to near confluence. The media was then removed and replaced with growth media containing 1% bovine serum albumin. After 24-hour serum starvation, compounds and specific growth factors were added and incubations continued for an additional 24 hours. During 15 the final 2 hours, ^{3}H -thymidine was added to the medium. To terminate the incubations, the medium was removed and cell layers washed twice with ice-cold phosphate-buffered saline. After the final wash, ice-cold 5% trichloroacetic acid was added and the cells incubated for 15 minutes at room temperature. The trichloroacetic acid solution was then removed and the cell layer washed three 20 times with distilled water. After the final wash, the cell layer was solubilized by addition of 2% sodium dodecylsulfate. Radioactivity in this solution was determined by scintillation counting.

In 3T3-L1 adipocyte cells, in which the inhibition blocks MAPK activation by insulin with an IC_{50} of 3 μM , the compound had no effect on the 25 insulin stimulated uptake of radiolabeled 2-deoxyglucose, or on the insulin-stimulated synthesis of either lipid or glycogen at 10 μM concentration. This demonstrates that the inhibitor shows selectivity between the mitogenic and metabolic effects of insulin, and demonstrates that the inhibitor will show less toxicity than an inhibitor which does not show this surprising selectivity.

Monolayer growth

Cells were plated into multi-well plates at 10 to 20,000 cells/mL. Forty-eight hours after seeding, compounds were added to the cell growth medium and incubation was continued for 2 additional days. Cells were then removed from the wells by incubation with trypsin and enumerated with a Coulter counter.

Growth in soft-agar

Cells were seeded into 35-mm dishes at 5 to 10,000 cells/dish using growth medium containing 0.3% agar. After chilling to solidify the agar, cells were transferred to a 37°C incubator. After 7 to 10 days growth, visible colonies were manually enumerated with the aid of a dissecting microscope.

Order of addition experiments established that the invention compounds are inhibiting MEK and not MAP kinase. Experiments looking at the phosphorylation of a kinase defective mutant of MAP kinase as substrate (so that there can be no autophosphorylation of the MAP kinase to complicate interpretation) confirms that the inhibitor inhibits MEK with an IC₅₀ essentially identical to that produced in the cascade assay.

Kinetic analysis demonstrates that the invention compounds are not competitive with ATP. Thus, they do not bind at the ATP binding site of the enzyme, which is probably the explanation as to why these compounds do not show the nonspecific kinase inhibitory activity typical of most kinase inhibitors, which do bind at the ATP binding site and which are ATP competitive.

The in vitro and in vivo biological activity of several representative compounds of Formula I in the foregoing assays is presented in Table 1. Data for several known compounds is also presented.

-37-

TABLE I

Compound of Example No.	In vitro IC ₅₀ (μM)	In vivo (cell culture) IC ₅₀ (μM)
1	0.007	0.05
2	0.003	0.03
3	0.072	3
4	0.023	1
5	0.566	~30
6	0.345	~30
7	0.221	<30
8	7.13	3
9	0.409	1
11	0.334	0.5
12	0.826	
13	0.243	
14	0.061	>2
17	0.014	
20	0.042	0.17
21	0.014	
22	0.137	
23	0.016	
24	0.021	0.12
25	0.102	
27	0.026	
28	0.728	
29	0.076	0.73
30	0.971	
31	0.045	
32	0.017	
33	0.374	
34	0.113	1.5

-38-

TABLE 1 (cont'd)

Compound of Example No.	In vitro IC 50 (μM)	In vivo (cell culture) IC 50 (μM)
36	0.056	0.07
37	0.002	
38	0.077	0.065
39	0.147	
40	0.028	0.125
41	0.236	
42	0.087	
43	0.040	0.100
44	0.475	
45	0.126	
47	0.087	0.13
49	0.085	
50	0.043	0.22
53	0.140	
55	0.047	
56	0.014	
57	0.181	
58	0.018	0.014
59	0.259	
62	0.086	
63	0.019	
64	0.279	
65	0.057	
66	0.016	0.13
68	0.119	
69	0.016	
70	0.224	
71	0.015	0.39
74	0.035	


-39-

TABLE 1 (cont'd)

Compound of Example No.	In vitro IC 50 (μ M)	In vivo (cell culture) IC 50 (μ M)
77	0.28	
78	0.080	
79	0.008	
80	0.080	
81	0.017	
82	0.003	0.04
83	0.031	
84	0.001	0.005
85	0.024	
86	0.047	
87	<0.001	
88	0.069	
89	0.005	0.30
90	0.055	
91	0.020	
92	0.033	
93	0.010	0.05
94	0.038	
95	0.001	
96	<0.010	
97	0.015	
98	0.025	
99	0.018	0.50
100	0.026	>1
101	0.008	>1
102	0.004	0.20


The following compounds, which are disclosed in United States Patent No. 5,155,110, were also evaluated in the foregoing assays, and each such compound demonstrated little or no inhibitory activity.

-40-



R ₆	R ₇	% Inhibition In Vitro
H	H	9 at 1 μ M -3 at 10 μ M
H	CH ₃	-8 at 1 μ M 8 at 10 μ M
CH ₃	H	-5 at 1 μ M 19 at 10 μ M
iPr	H	17 at 1 μ M 9 at 10 μ M
CH ₂ -Ph	H	-4 at 1 μ M 18 at 10 μ M

-41-



R ₆	R ₇	% Inhibition In Vitro
H	H	6 at 1 μ M -4 at 10 μ M
H	CH ₃	-6 at 1 μ M 12 at 10 μ M
CH ₃	H	13 at 1 μ M 19 at 10 μ M
iPr	H	-11 at 1 μ M 7 at 10 μ M

EXAMPLE 103

The compound from Example 95, 2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, was evaluated in animals implanted with a murine colon tumor, C26/clone 10. Male CD2F1 mice (NCI: Charles River, Kingston) were implanted subcutaneously with tumor fragments (approximately 5 30 mg) in the region of the right axilla on Day 0. The compound of Example 95 was administered intraperitoneally (IP) or orally (PO) on Days 1 through 14, post-implant, for a total of 14 days (6 mice per group). The vehicle for the test compound, and for control animals, was 10% EtOH/10% Cremophor-EL (Sigma)/80% H₂O, pH 5.0. Tumor volumes were recorded three times per week by measuring the length and width of the individual tumors and calculating mass in milligrams according to the formula $(a \times b^2)/2$, where a and b are the length and width of the tumor. Percent treated/control (T/C) was calculated based on the ratio of the median tumor volume of the treated tumors compared with the median tumor volume of control animals on specified measurement days.

-42-

In the trial in which the compound of Example 95 was administered IP, the doses were 200, 124, 77, and 48 mg/kg/day. The invention compound inhibited tumor growth by 59% to 100% as assessed on Day 15. The median size of the control tumors on Day 15 was 1594 mg. Table 2 shows the number of animal deaths in each treatment group, the change in body weight, the percent of the median tumor volume of the treated group compared to the control group, and the percent inhibition.

TABLE 2

Dose	Non-Specific Deaths	Change in Body Weight (grams)	% T/C	% Inhibition
			(Day 15)	
200	1/6	+2	0	100
124	1/6	+3	4	96
77	2/5	+2	2	98
48	0/6	+3	41	59

In the test in which the compound of Example 95 was orally administered, the doses were 300, 186, 115, and 71 mg/kg/day. The invention compound inhibited tumor growth 64% to 83% as assessed on Day 17. The median size of the control tumors on Day 17 was 1664 mg. Table 3 shows the number of animal deaths in each treatment group, the change in body weight, the percent of the median tumor volume of the treated group compared to the control group, and the percent inhibition.

-43-

TABLE 3

Dose	Non-Specific Deaths	Change in Body Weight (grams)	% T/C.		% Inhibition
			(Day 17)		
300	0/6	+2	17	83	
186	0/6	+2	25	75	
115	1/6	+2	21	79	
71	0/6	+2	36	64	

The foregoing assay established that the invention compounds of Formula I are particularly useful for treating cancers such as colon cancer. The compounds are especially well-suited for use in combination with radiation to treat and control cancers.

5 The invention compounds will be utilized to treat subjects suffering from cancer and other proliferative diseases and in need of treatment. The compounds are ideally suited to treating psoriasis, restenosis, autoimmune disease, and atherosclerosis. The compounds will generally be utilized as a pharmaceutical formulation, in which the compound of Formula I is present in a concentration of about 5% to about 95% by weight. The compounds can be formulated for convenient oral, parenteral, topical, rectal, or like routes of administration. The compound will be formulated with common diluents, excipients, and carriers routinely utilized in medicine, for instance, with polyols such as glycerin, ethylene glycol, sorbitol 70; mono- and difatty acid esters of ethylene glycol. Starches and sugars such as corn starch, sucrose, lactose, and the like, can be utilized for solid preparations. Such solid formulations can be in the form of tablets, troches, pills, capsules, and the like. Flavoring agents such as peppermint, oil of wintergreen, and the like can be incorporated.

10 Typical doses of active compound are those that are effective to treat the cancer or other proliferative disorder afflicting the mammal. Doses will generally be from about 0.1 mg per kilogram body weight to about 500 mg per kilogram body weight. Such doses will be administered from one to about four times a day,

15

20

-44-

or as needed to effectively treat the cancer, psoriasis, restenosis, or other proliferative disorder.

A preferred method for delivering the invention compound is orally via a tablet, capsule, solution, or syrup. Another method is parenterally, especially via intravenous infusion of a solution of the benzopyran in isotonic saline or 5% aqueous glucose.

5 Following are typical formulations provided by the invention.

EXAMPLE 104

Preparation of 50-mg Tablets

Per Tablet		Per 10,000 Tablets
0.050 g	4-fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide	500 g
0.080 g	lactose	800 g
0.010 g	corn starch (for mix)	100 g
0.008 g	corn starch (for paste)	80 g
0.002 g	magnesium stearate (1%)	20 g
0.150 g		1500 g

10 The benzhydroxamic acid, lactose, and corn starch (for mix) are blended to uniformity. The corn starch (for paste) is suspended in 600 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The granules are passed through a #8 screen and dried at 120°F. The dry granules are passed through a #16 screen. The mixture is lubricated with 1% magnesium stearate and compressed into tablets. The tablets are administered to a 15 mammal for inhibiting MEK enzymes and treating restenosis, atherosclerosis, and psoriasis.

-45-

EXAMPLE 105

Preparation of Oral Suspension

Ingredient	Amount
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(methoxy)-benzamide	500 mg
Sorbitol solution (70% NF)	40 mL
Sodium benzoate	150 mg
Saccharin	10 mg
Red dye	10 mg
Cherry flavor	50 mg
<u>Distilled water qs ad</u>	<u>100 mL</u>

The sorbitol solution is added to 40 mL of distilled water and the benzhydroxamic acid derivative is suspended therein. The saccharin, sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 5 mg of the invention compound. The syrup is administered to a mammal for treating proliferative disease, especially breast cancer and skin cancer.

EXAMPLE 106

Preparation of Parenteral Solution

In a solution of 700 mL of propylene glycol and 200 mL of water for injection is added 20.0 g of 4-fluoro-2-(4-bromo-2-methyl-phenylamino)-N-(hydroxy)-benzamide. The volume of the solution is adjusted to 1000 mL by addition of water for injection. The formulation is heat sterilized, filled into 50-mL ampoules each containing 2.0 mL (40 mg of 4-fluoro-2-(4-bromo-2-methyl-phenylamino)-N-(hydroxy)-benzamide), and sealed under nitrogen.

The invention compounds thus formulated will be administered to a mammal in need of treatment for a proliferative disorder such as cancer, psoriasis, restenosis, atherosclerosis, and autoimmune disease at a rate and dose effective to treat the condition. An "antiproliferative amount" of an invention compound is

-46-


that quantity of compound that inhibits or reduces the rate of proliferation of target cells. Typical cancers to be treated according to this invention include breast cancer, colon cancer, prostate cancer, skin cancer, and the like. The compound is well-suited to the treatment of psoriasis, restenosis, and 5 atherosclerosis, and to inhibiting the activity of MEK enzymes, especially MEK₁ and MEK₂. All that is required is to administer to a mammal an MEK inhibiting amount of a compound of the invention. An "MEK inhibiting amount" of an invention compound is an amount that when administered to a mammal causes a measurable inhibition of the MEK enzyme. Typical MEK inhibiting 10 amounts will be from about 0.1 µg to about 500 mg of active compound per kilogram body weight. For treating the proliferative diseases mentioned above, typical doses will be from about 0.1 to about 50 mg/kg, normally given from one to about four times per day.

-47-

CLAIMS

What is claimed is:

1. The compounds are defined by Formula I



5

wherein:

R₁ is hydrogen, hydroxy, C₁-C₈ alkyl, C₁-C₈ alkoxy, halo,

trifluoromethyl, or CN;

R₂ is hydrogen;

R₃, R₄, and R₅ independently are hydrogen, hydroxy, halo,

trifluoromethyl, C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, CN, or

(O or NH)_m-(CH₂)_n-R₉, where R₉ is hydrogen, hydroxy, CO₂H

or NR₁₀R₁₁;

n is 0 to 4;

m is 0 or 1;

10 R₁₀ and R₁₁ independently are hydrogen or C₁-C₈ alkyl, or taken

together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or

N-C₁-C₈ alkyl;

15




R₆ is hydrogen, C₁-C₈ alkyl, C-C₁-C₈ alkyl, aryl, aralkyl, or

20 C₃-C₁₀ cycloalkyl;

-48-

R₇ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₁₀ (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or NR₉); and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by cycloalkyl (or cycloalkyl optionally containing a heteroatom selected from O, S, or NR₉), aryl, aryloxy, heteroaryl, or heteroaryloxy; or R₆ and R₇ taken together with the N-0 to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or NR₁₀R₁₁.

2. A compound according to Claim 1 wherein R₁ is C₁-C₈ alkyl or halo.
3. A compound according to Claim 2 wherein R₆ is hydrogen.
4. A compound according to Claim 3 wherein R₁ is methyl.
5. A compound according to Claim 4 having the formula



6. A compound of Claim 5 wherein R₄ is fluoro, and R₃ and R₅ are hydrogen.
7. A compound of Claim 6 which is:
 - 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
 - 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(methoxy)-benzamide;

20

-49-

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-nyloxy)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;

5 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-enyloxy)-benzamide;

10 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentoxy)-benzamide;

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-isopropyl-benzamide; and

15 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide.

8. A compound of Claim 5 wherein R₃ and R₄ are fluoro, and R₅ is hydrogen.

9. A compound of Claim 8 which is:

20 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-ethoxy-benzamide;

25 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methylprop-2-nyloxy)-benzamide;

30 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenylprop-2-nyloxy)-benzamide;

-50-

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-5-phenylpent-2-en-4-nyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-nyloxy)-benzamide;

5 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(propoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclobutyloxy)-benzamide;

10 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-prop-2-nyloxy)-benzamide;

15 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-nyloxy)-benzamide;

20 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-3-nyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentyloxy)-benzamide;

25 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-nyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-nyloxy)-benzamide;

3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

30 3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-(tetrahydro-pyran-2-nyloxy)-benzamide; and

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide.

-51-

10. A compound of Claim 5 wherein R₃ and R₄ are fluoro, and R₅ is bromo.

11. A compound according to Claim 10 which is:

5-Bromo-3,4-difluoro-N-hydroxy-2-(4-ido-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(n-propoxy)-benzamide;

5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-ido-2-methyl-phenylamino)-benzamide;

5-Bromo-N-(but-2-enoxy)-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-benzamide

5-Bromo-N-butoxy-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(3-methyl-but-2-enoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(3-methyl-pent-2-en-4-ynoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-benzyl)-N-[5-(3-methoxy-phenyl)-3-methyl-pent-2-en-4-ynoxy]-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(prop-2-ynoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-[3-(3-methoxy-phenyl)-prop-2-ynoxy]-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(thiopen-2-ylmethoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(pyridin-3-ylmethoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(ethoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-ido-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;

-52-

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-but-3-ynyl-oxo-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethoxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethoxy)-benzamide;

5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isobutoxy-benzamide;

5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;

5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide; and

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide.

12. A compound of Claim 5 wherein R₃ and R₄ are hydrogen, and R₅ is halo.

-53-

13. A compound according to Claim 12 which is:

5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;

5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide;

4-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;


10 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;

5-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide; and

15 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydropyran-2-yloxy)-benzamide.

14. A compound of Claim 4 having the formula



15. A compound of Claim 14 wherein R₃ and R₄ are fluoro, and R₅ is

20 hydrogen.

16. A compound according to Claim 15 which is:

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynloxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;

5 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-3-ynyoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-methylprop-2-enyloxy)-benzamide;

10 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(methoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(ethoxy)-benzamide;

15 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclobutoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;

20 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide;

25 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-(3-fluorophenyl)-prop-2-ynyoxy)-benzamide;

30 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(4,4-dimethylpent-2-ynyoxy)-benzamide; and

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopentoxy)-benzamide.

-55-

17. A compound according to Claim 1 which is:

3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

10 2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;

15 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

20 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

25 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide;

30 2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

5 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

10 N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

15 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

20 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide;

25 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

30 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

-57-

2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluoro-benzamide

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide;

5 N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

10 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

15 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

20 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;

3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

25 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide (HCl salt);

2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

30 2-(2-Chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-3,4-difluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

-58-

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;

5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

10


2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; and

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide.


18. A pharmaceutical formulation comprising a compound of Claim 1 admixed with a pharmaceutically acceptable excipient, diluent, or carrier.

15

19. A formulation of Claim 18 comprising a compound of the formula



20. A formulation of Claim 18 comprising a compound of the formula



-59-

21. A method for inhibiting MEK enzymes in a mammal comprising administering an MEK inhibiting amount of a compound of Claim 1.
22. A method of treating a mammal suffering from a proliferative disease and in need of treatment comprising administering an antiproliferative amount of a compound of Claim 1.
5
23. A method according to Claim 21 wherein the proliferative disease is psoriasis, restenosis, autoimmune disease, or atherosclerosis.
24. A method according to Claim 21 wherein the proliferative disease is cancer.
- 10 25. A method for treating a mammal suffering from stroke and in need of treatment comprising administering an effective amount of a Compound of Claim 1.
26. A method for treating a mammal suffering from heart failure and in need of treatment comprising administering an effective amount of a Compound
15 of Claim 1.
27. A method for treating a mammal suffering from hepatomegaly and in need of treatment comprising administering an effective amount of a Compound of Claim 1.
28. A method for treating a mammal suffering from cardiomegaly and in need of treatment comprising administering an effective amount of a Compound
20 of Claim 1.
29. A method for treating a mammal suffering from diabetes and in need of treatment comprising administering an effective amount of a Compound of Claim 1.

-60-

30. A method for treating a mammal suffering from Alzheimer's disease and in need of treatment comprising administering an effective amount of a Compound of Claim 1.
31. A method for treating a mammal suffering from cancer comprising administering an effective amount of a compound of Claim 1 in conjunction with conventional radiation therapy.
32. A method for treating a mammal suffering from cystic fibrosis and in need of treatment comprising administering an effective amount of a compound of Claim 1.

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 98/13106	

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6	C07C259/10	C07D295/08	C07D309/12	A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC				
---	--	--	--	--

B. FIELDS SEARCHED				
---------------------------	--	--	--	--

Minimum documentation searched (classification system followed by classification symbols)				
---	--	--	--	--

IPC 6 C07C C07D A61K				
----------------------	--	--	--	--

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
---	--	--	--	--

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
--	--	--	--	--

C. DOCUMENTS CONSIDERED TO BE RELEVANT				
---	--	--	--	--

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 98 37881 A (WARNER LAMBERT) 3 September 1998 see page 15, line 1 - page 22, line 29 see page 53, line 5 - page 77, line 5 see page 80 - page 81; claims 8,9 ----	1-32
A	US 5 525 625 A (ALEXANDER J. BRIDGES ET AL.) 11 June 1996 see the whole document -----	1-32

<input type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
---	--

* Special categories of cited documents :	
---	--

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 October 1998	28/10/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Zervas, B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13106

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 21-32 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13106

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9837881	A 03-09-1998	NONE		
US 5525625	A 11-06-1996	AU 690400 B		23-04-1998
		AU 4245696 A		14-08-1996
		CA 2208075 A		01-08-1996
		EP 0805807 A		12-11-1997
		WO 9622985 A		01-08-1996

